Innate Pharma S.A. (LON:0EVI)
1.590
-0.024 (-1.49%)
At close: Dec 17, 2025
Innate Pharma Revenue
Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.
Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
11.71
Revenue / Employee
69.81K EUR
Employees
181
Market Cap
126.80M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |